Vui lòng sử dụng định danh này để trích dẫn hoặc liên kết đến tài liệu: http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/385
Nhan đề : Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
Tác giả : Hallek, Michael
Năm xuất bản : 2013
Nhà xuất bản : American Society of Hematology
Tóm tắt : The management of chronic lymphocytic leukemia (CLL) is undergoing profound changes. Several new drugs have been approved for CLL treatment (fludarabine, bendamustine, and the monoclonal antibodies alemtuzumab, rituximab, and ofatumumab) and many more drugs are in advanced clinical development to be approved for this disease. In addition, the extreme heterogeneity of the clinical course and our improved ability to foresee the prognosis of this leukemia by the use of clinical, biological, and genetic parameters now allow us to characterize patients with a very mild onset and course, an intermediate prognosis, or a very aggressive course with high-risk leukemia. Therefore, it becomes increasingly challenging to select the right treatment strategy for each condition. This article summarizes the currently available diagnostic and therapeutic tools and gives an integrated recommendation of how to manage CLL in 2013. Moreover, I propose a strategy how we might integrate the novel agents for CLL therapy into sequential treatment approaches in the near future.
URI: http://220.231.117.85:8000/handle/DHKTYTHD_123/385
Bộ sưu tậpHuyết học = Hematology

Danh sách tệp tin đính kèm:
Tên tệp tin Mô tả tệp tin Dung lượngĐịnh dạng  
Hematology-2013-Hallek-138-50.pdf
  Restricted Access
1.15 MBAdobe PDFẢnh bìa
 Gửi yêu cầu


Khi sử dụng tài liệu trong thư viện số bạn đọc phải tuân thủ đầy đủ luật bản quyền.